Search
Cardiolipin Biosynthesis CL(8:0/10:0/i-17:0/i-18:0)
smpdb.ca/view/SMP0228479MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/10:0/i-17:0/i-24:0)
smpdb.ca/view/SMP0228483MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/10:0/i-19:0/a-25:0)
smpdb.ca/view/SMP0228505MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/10:0/i-19:0/i-21:0)
smpdb.ca/view/SMP0228508MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/10:0/i-19:0/i-24:0)
smpdb.ca/view/SMP0228510MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/10:0/i-22:0/a-25:0)
smpdb.ca/view/SMP0228523MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(8:0/10:0/i-24:0/a-25:0)
smpdb.ca/view/SMP0228527MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Ningetinib
go.drugbank.com/drugs/DB16256InvestigationalNingetinib is under investigation in clinical trial NCT03758287 (Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative).
Synonyms: Ct-053 free base, Ct053ptsa free baseCantharidin
go.drugbank.com/drugs/DB12328ApprovedInvestigational[L47496] The approval was based on positive results from 2 phase III trials, CAMP-1 and CAMP-2, where 46% and 52% of patients treated with cantharidin achieved complete molluscum clearance, respectively … [A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients
Mixtures: CANTHACUR PS %1,%5,%30 TOPIKAL SOLUSYON 7,5 ML, Cantharidin 1% / Podophyllum Resin 5% / Salicylic Acid 30%Categories: Heterocyclic Compounds, 2-RingCloxazolam
go.drugbank.com/drugs/DB01553ExperimentalAs well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. … Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis.
Categories: Heterocyclic Compounds, 2-RingProducts: OLCADIL ® 2 MG COMPRIMIDOS, OLCADIL ® 1 MG COMPRIMIDOS